US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
UK-based biopharmaceutical company Ario Pharma has announced the appointment of Professor Peter Barnes and Professor Wisia Wedzicha to its Scientific Advisory Board with immediate effect. 12 May 2014
Germany’s Merck (MRK: DE) has appointed Marcus Kuhnert as Group Chief Financial Officer. Mr Kuhnert will become a member of Merck’s Executive Board with unlimited personal liability as of August 1, 2014. 9 May 2014
US-based Eleven Biotherapeutics (Nasdaq: EBIO), a clinical-stage biopharmaceutical company developing protein therapeutics to treat eye diseases, has announced the appointment of Gary Sternberg as Executive Vice President of Corporate and Business Development. 8 May 2014
Cobra Biologics is pleased to announce the appointment of Daniel Smith as Chief Scientific Officer with the responsibility of enhancing Cobra’s DNA, virus, microbial and mammalian proteins research and development platforms. 7 May 2014
UK-based GW Pharmaceuticals has announced the appointment of Kenneth Sommerville to the newly created position of VP, Clinical Science, based in the USA. 7 May 2014
US-based pharmacogenetics company Millennium Laboratories has announced the appointment of Nikhil Nayak as chief marketing officer, Steven Soe as chief compliance officer, and Michael Flowers as vice president, government operations. 6 May 2014
Japanese drug major Astellas Pharma has announced the promotions of Bernhardt Zeiher to executive vice president, Global Development and Jeannette Barrett to vice president and head of Medical Excellence, Global Medical Affairs. 6 May 2014
UK-based cancer therapeutics firm Scancell has announced the appointment of Sally Adams to the board as Development Director with immediate effect. 1 May 2014
UK nanotechnology firm Midatech has announced the appointments of Rolf Stahel as chairman and Craig Cook as Chief Operating Officer (COO) and Chief Medical Officer (CMO). 1 May 2014
US biopharmaceutical company Coherus Biosciences has announced the appointment of Michael Fleming as senior vice president, commercial strategy. 28 April 2014
UK-based antiviral drug discovery and development company reViral has announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014. 28 April 2014
Novartis Vaccines, the vaccination branch of Swiss drug major Novartis (NOVN: VX), has announced the appointment of Dr John Porter to the position of Medical Affairs Director for Cluster North Europe. 25 April 2014
Digital medicines company Proteus Health, have announced the expansion of the company’s executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals. 25 April 2014
China’s WuXi PharmaTech (NYSE: WX) has announced that Dr Steve Yang has joined the company as Executive Vice President and Chief Operating Officer. Edward Hu will assume new responsibilities as Chief Investment Officer and remain as Chief Financial Officer. 24 April 2014
US generic drugmaker Impax Laboratories (NASDAQ: IPXL) has announced the appointment of Frederick Wilkinson as President and Chief Executive Officer effective April 29, 2014. 24 April 2014